Anaphylaxis: a payor's perspective on epinephrine autoinjectors

Area of Science:

• Health Economics
• Allergy and Immunology
• Public Health

Background:

• Anaphylaxis expenditures are underestimated by healthcare payors due to underdiagnosis and focus on direct medical costs.
• Current estimates place direct costs at $1.2 billion annually, including $294 million for epinephrine and $609 million in indirect costs.

Purpose of the Study:

• To highlight the underestimation of anaphylaxis costs by healthcare payors.
• To emphasize the need for improved diagnostic coding and treatment strategies for cost containment.
• To explore the role of epinephrine autoinjectors and managed care in managing anaphylaxis costs.

Main Methods:

• Analysis of existing data on anaphylaxis expenditures.
• Review of diagnostic coding practices and their impact on cost assessment.
• Examination of treatment guidelines and the role of epinephrine autoinjectors.

Main Results:

• More accurate diagnostic coding can improve understanding of anaphylaxis' full impact.
• Improved diagnosis and treatment can lead to direct cost savings (e.g., fewer emergency visits) and indirect savings (e.g., increased productivity).
• The cost of improper anaphylaxis response and treatment exceeds the increasing cost of epinephrine autoinjectors.

Conclusions:

• Accurate diagnosis and coding are essential for payors to grasp the full economic burden of anaphylaxis.
• Enhanced medical education on anaphylaxis treatment, particularly epinephrine autoinjector use, can drive cost savings.
• Addressing access barriers and promoting patient education are critical for effective anaphylaxis management and cost reduction.